A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes

Cancer Research

Volumn 71, Issue 3, 2011, Pages 1050-1059

  Tafreshi, Narges K ^a   Enkemann, Steven A ^a   Bui, Marilyn M ^a   Lloyd, Mark C ^a   Abrahams, Dominique ^b   Huynh, Amanda S ^a   Kim, Jongphil ^a   Grobmyer, Stephen R ^c   Carter, W Bradford ^a   Vagner, Josef ^d   Gillies, Robert J ^a   Morse, David L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORESCENT DYE; MAMAB 680; MAMMAGLOBIN; MAMMAGLOBIN A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CELL SURFACE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DRUG CONJUGATION; DRUG RETENTION; DRUG SELECTIVITY; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TISSUE MICROARRAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENT DYES; HUMANS; IMMUNOCONJUGATES; LYMPH NODES; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM PROTEINS; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; UTEROGLOBIN;

EID: 79551549744     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3091     Document Type: Article

References (49)

1. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-83.
2. Tafreshi NK, Kumar V, Morse DL, Gatenby RA. Molecular and functional imaging of breast cancer. Cancer Control 2010;17:143-55.
3. NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. Oncology 1991;5:120-4.
4. Mariani G, Erba P, Villa G, Gipponi M, Manca G, Boni G, et al. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective. J Surg Oncol 2004;85:112-22.
5. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997;349:1668-9.
6. Maza S, Valencia R, Geworski L, Zander A, Guski H, Winzer KJ, et al. Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging 2003;30:651-6.
7. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23:4312-21.
8. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998;339:941-6.
9. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
10. Ung OA. Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg 2004;27:284-90.
11. Krag DN, Anderson SJ, Julian TB, Brown A, Harlow SP, Costantino JP, et al. Primary outcome results of NSABP-32, a randomized phase III trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol 2010;28:18s.
12. Ibusuki M, Yamamoto Y, Kawasoe T, Shiraishi S, Tomiguchi S, Yamashita Y, et al. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system. Surg Oncol 2010;19:88-94.
13. Van Der Ploeg IM, Valdes Olmos RA, Kroon BB, Nieweg OE. The Hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg 2008;32:1930-4.
14. Makale M, McElroy M, O'Brien P, Hoffman RM, Guo S, Bouvet M, et al. Extended-working-distance multiphoton micromanipulation microscope for deep-penetration imaging in live mice and tissue. J Biomed Opt 2009;14:024032.
15. Mortellaro VE, Marshall J, Singer L, Hochwald SN, Chang M, Copeland EM, et al. Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 2009;30:309-12.
16. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004;22:93-7.
17. Kobayashi H, Hama Y, Koyama Y, Barrett T, Regino CA, Urano Y, et al. Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett 2007;7:1711-6.
18. Kobayashi H, Ogawa M, Kosaka N, Choyke PL, Urano Y. Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine 2009;4:411-9.
19. Ogata F, Azuma R, Kikuchi M, Koshima I, Morimoto Y. Novel lymphography using indocyanine green dye for near-infrared fluorescence labeling. Ann Plast Surg 2007;58:652-5. (Pubitemid 46816803)
20. Pramanik M, Song KH, Swierczewska M, Green D, Sitharaman B, Wang LV. In vivo carbon nanotube-enhanced non-invasive photoacoustic mapping of the sentinel lymph node. Phys Med Biol 2009;54:3291-301.
21. Kim JW, Galanzha EI, Shashkov EV, Moon HM, Zharov VP. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat Nanotechnol 2009;4:688-94.
22. Song KH, Kim C, Cobley CM, Xia Y, Wang LV. Near-infrared gold nanocages as a new class of tracers for photoacoustic sentinel lymph node mapping on a rat model. Nano Lett 2009;9:183-8.
23. Song KH, Kim C, Maslov K, Wang LV. Noninvasive in vivo spectroscopic nanorod-contrast photoacoustic mapping of sentinel lymph nodes. Eur J Radiol 2009;70:227-31.
24. Song KH, Stein EW, Margenthaler JA, Wang LV. Noninvasive photoacoustic identification of sentinel lymph nodes containing methylene blue in vivo in a rat model. J Biomed Opt 2008;13:054033.
25. Pan D, Pramanik M, Senpan A, Ghosh S, Wickline SA, Wang LV, et al. Near infrared photoacoustic detection of sentinel lymph nodes with gold nanobeacons. Biomaterials 2010;31:4088-93.
26. Abdul-Rasool S, Kidson SH, Panieri E, Dent D, Pillay K, Hanekom GS. An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol 2006;59:289-97. (Pubitemid 43344892)
27. Douglas-Jones AG, Woods V. Molecular assessment of sentinel lymph node in breast cancer management. Histopathology 2009;55:107-13.
28. Inokuchi M, Ninomiya I, Tsugawa K, Terada I, Miwa K. Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer 2003;89:1750-6. (Pubitemid 37464150)
29. Backus J, Laughlin T, Wang Y, Belly R, White R, Baden J, et al. Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. J Mol Diagn 2005; 7:327-36.
30. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999;59:3028-31.
31. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-5.
32. Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004;37:249-57.
33. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004;4:531-42.
34. Zuo L, Li L, Wang Q, Fleming TP, You S. Mammaglobin as a potential molecular target for breastcancer drug delivery. Cancer Cell Int 2009;9:8.
35. Guan XF, Hamedani MK, Adeyinka A, Walker C, Kemp A, Murphy LC, et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 2003;21:245-50.
36. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998;58:4581-4.
37. Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knüchel R, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006;6:88.
38. Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2005;342:69-77. (Pubitemid 40805630)
39. Schlauder SM, Steffensen TS, Morgan M, Letson DG, Pledger WJ, Ma L, et al. Assessment of muscarinic and nicotinic acetylcholine receptor expression in primitive neuroectodermal tumor/ewing family of tumor and desmoplastic small round cell tumor: an immunohistochemical and Western blot study of tissue microarray and cell lines. Fetal Pediatr Pathol 2008;27:83-97. (Pubitemid 351883392)
40. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-13. (Pubitemid 46797025)
41. Han JH, Kang Y, Shin HC, Kim HS, Kang YM, Kim YB, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med 2003;127:1330-4.
42. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breastspecific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007; 20:208-14.
43. Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol 2009;2:384-9.
44. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990;50:717-21.
45. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-80.
46. Greene FL. AJCC Cancer Staging Handbook-TNM Classification of Malignant Tumors. New York: Springer; 2002.
47. Sobin LH. UICC TNM Classification of Malignant Tumors. Chichester, UK: John Wiley & Sons; 2002.
48. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-52.
49. Sharma P, Brown SC, Bengtsson N, Zhang Q, Walter GA, Grobmyer SR, et al. Gold-speckled multimodal nanoparticles for noninvasive bioimaging. Chem Mater 2008;20:6087-94.